Product Wiki · Recalls · Health Canada Consumer Product Safety

Recall 59261 — Clinical trial finds an increased risk of blood clots in the lungs and of death in rheumatoid arthritis patients taking high dose of tofacitinib (sold as Xeljanz or Xeljanz XR)

Health Canada Consumer Product Safety · Canada · 2019-03-15

AI-assisted, human-edited — this page is drafted with AI from public-source data, then reviewed before publication. How we use AI →
Agency
Health Canada Consumer Product Safety
Recall identifier
59261
Date of alert
2019-03-15
Country / jurisdiction
Canada
Risk type
recall
Product category
Drugs
Product type
Communications and Public Affairs Branch
Reported risk: Product safety
Primary source: https://recalls-rappels.canada.ca/en/alert-recall/clinical-trial-finds-increased

Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.

Related

ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.